The Biden administration seems to think it knows better than doctors how to practice medicine. But his haphazard micromanagement of mono...
The Biden administration seems to think it knows better than doctors how to practice medicine. But his haphazard micromanagement of monoclonal antibodies to treat Covid-19 has created supply shortages, sown confusion, likely harmed patients and undermined future treatments.
The Food and Drug Administration has granted emergency use authorizations for three monoclonal antibody preparations to treat Covid patients who have mild to moderate symptoms and are at high risk of progressing to severe disease. These authorizations covered a treatment developed by Regeneron, one from Eli Lilly and one from GlaxoSmithKline. These lab-made proteins provide antibodies to fight Covid faster than our bodies can make them, reducing the risk of hospitalization and death.
COMMENTS